Vivos Therapeutics, Inc. VVOS

Vivos Therapeutics, Inc. (VVOS) announces material debt reduction. Material debt reduction improves balance sheet strength and may support operational flexibility.

Vivos Therapeutics signed definitive agreements with South Palm Cardiovascular Associates to launch a regional sleep testing and treatment center. Agreement launches one regional center to expand Vivos sleep treatment operations.

Vivos Therapeutics opens new sleep testing and treatment facility in Nevada to meet growing patient demand for sleep apnea services. New facility expands operational capacity in core sleep apnea segment to capture rising demand.

Vivos Therapeutics Inc reported 35% revenue growth in Q2 2026 earnings call. 35% revenue surge reflects strong operational gains that can materially lift valuation and sentiment.

Vivos Therapeutics held its Q2 2026 earnings call covering financial results, operational updates and forward outlook for the company. Quarterly earnings calls typically supply financial metrics and guidance that moderately influence near-term stock sentiment and operations.

Vivos Therapeutics reported a Q2 net loss and missed revenue estimates. Q2 loss combined with revenue shortfall signals potential short-term pressure on stock price and investor sentiment.

Vivos Therapeutics reported second quarter 2026 financial results along with an operational update. Quarterly financial reports and operational updates can moderately shift investor views on performance and outlook.

Vivos Therapeutics expands Greenway Health partnership to deploy AI-enabled platform across all clinical and revenue operations. AI platform rollout across all operations represents a major strategic move likely to improve efficiency and alter company trajectory.

Vivos Therapeutics, Inc. (VVOS) has secured a new U.S. patent that expands protection for its Vivos CARE Technology. New patent expands intellectual property coverage for core Vivos CARE Technology, supporting competitive positioning.

Vivos Therapeutics receives new US patent broadening protection for Vivos CARE oral medical device technology. New patent broadens protection for core device with moderate competitive impact.

Vivos Therapeutics' Vida appliance showed statistically significant improvement in insomnia severity in 100% of study participants. Strong positive study results on core Vida product support regulatory progress and revenue growth potential.

Vivos Therapeutics and Streeterville extended the timeframe of their strategic financing agreement while reaffirming commitment to convert debt into common stock and perpetual preferred equity. Debt conversion extension improves balance sheet flexibility and reduces near-term repayment risk for VVOS.

Vivos Therapeutics plans to file for a proposed rights offering. Rights offering enables capital raise affecting financial structure and shareholder equity.

Vivos Therapeutics intends to file a registration statement for a proposed rights offering. Rights offering signals capital raise that may affect share structure and financial position.

Vivos Therapeutics partners with multi-location Florida cardiology group to deliver sleep apnea and insomnia diagnosis and treatment to cardiovascular patients. Florida cardiology collaboration expands Vivos sleep disorder treatment access to cardiovascular patients.

Vivos Therapeutics enters binding agreement to exchange up to $4.5 million senior debt for equity with Streeterville Capital to maintain Nasdaq listing compliance. Debt-to-equity exchange reduces liabilities and secures Nasdaq listing for Vivos Therapeutics.

Vivos Therapeutics reported surging revenue in Q1 2026 amid ongoing strategic shifts. Revenue surge combined with strategic shifts signals major positive changes to financial trajectory and investor outlook.

Vivos Therapeutics, Inc. released a summary of its Q1 2026 earnings call covering quarterly financial results and business updates. Quarterly earnings updates provide financial and operational details that moderately affect short-term stock sentiment and valuation.

Vivos Therapeutics reported financial results for the first quarter of 2026 and provided an operational update. Quarterly results and updates offer performance details that can shift near-term investor views without altering long-term strategy.

Vivos Therapeutics Inc. (VVOS) Q4 2025 earnings call highlighted revenue growth amid strategic initiatives. Q4 2025 revenue growth and strategic developments represent major financial and operational progress likely to significantly enhance future performance and investor sentiment.

Vivos Therapeutics, Inc. (VVOS) reported full-year 2025 financial results, detailing revenue, expenses, and key operational metrics. Full-year financial results directly impact financial performance, investor sentiment, and stock trajectory for VVOS.

Vivos Therapeutics, Inc. released Q4 2025 earnings call summary highlighting financial results, operational updates, and future outlook for the sleep apnea treatment company. Q4 earnings call summaries disclose critical financial metrics, revenue growth, and strategic guidance that drive stock volatility and long-term investor expectations.

Vivos Therapeutics, Inc. (VVOS) completed a private placement with its existing private equity investor, New Seneca Partners. Private placement completion provides needed capital infusion, moderately bolstering short-term financial stability and market sentiment.

Vivos Therapeutics reports that its supported professional practices have achieved 'in-network' status across multiple commercial health insurers and Medicare in the key Nevada market. In-network status with major insurers expands reimbursement access and patient volume in a key market, significantly boosting revenue potential and market penetration.

Recent study confirms fundamental correlation between obstructive sleep apnea severity and oral anatomy, validating Vivos Therapeutics, Inc. (VVOS) oral appliance therapies for treatment. Scientific validation of OSA-oral anatomy link bolsters VVOS's core treatment efficacy and investor confidence.

Vivos Therapeutics, Inc. has announced a collaboration with SoundHealth to enhance access to SoundHealth's FDA-cleared allergy and sleep technologies. This partnership aims to leverage Vivos' expertise in sleep-disordered breathing and expand the reach of innovative health solutions to a broader audience. The collaboration is expected to significantly enhance Vivos' product offerings and market presence in the health technology sector.

Vivos Therapeutics, Inc. has signed a 12-part media series with New to The Street, aimed at enhancing its visibility and outreach. This collaboration is expected to showcase the company's innovative solutions in the field of sleep-disordered breathing and expand its audience reach through various media platforms. The media series could moderately enhance brand awareness and market sentiment, impacting the company's competitive positioning.

Vivos Therapeutics, Inc. has successfully closed the exercise of warrants, resulting in gross proceeds of $4.64 million. This financial move is expected to bolster the company's capital position and support its ongoing initiatives. The exercise of warrants provides additional capital that may enhance financial performance and support strategic initiatives.

Vivos Therapeutics, Inc. announced the exercise of warrants, resulting in gross proceeds of $4.64 million. This financial move is expected to bolster the company's capital position, supporting its ongoing initiatives and growth strategies. The exercise of warrants provides additional capital that may enhance financial performance and support strategic initiatives.

Vivos Therapeutics, Inc. (VVOS) has been upgraded to a 'Buy' rating by analysts, reflecting positive sentiment regarding the company's growth potential and market position. The upgrade is based on recent developments in their product offerings and strategic initiatives aimed at expanding their reach in the sleep apnea treatment market. Investors are encouraged to consider this upgrade as a signal of confidence in Vivos' future performance. The upgrade to 'Buy' indicates significant confidence in Vivos' strategic direction and market potential.